<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology, clinical manifestations, and diagnosis of migraine in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology, clinical manifestations, and diagnosis of migraine in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology, clinical manifestations, and diagnosis of migraine in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Michael Cutrer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21673885"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Migraine is an episodic disorder, the centerpiece of which is a severe headache generally associated with nausea and/or light and sound sensitivity. It is one of the most common complaints encountered by neurologists in day-to-day practice.</p><p>The pathophysiology, clinical manifestations, diagnosis, and complications of migraine will be reviewed here. Other aspects of migraine are discussed separately. (See  <a class="medical medical_review" href="/d/html/3347.html" rel="external">"Acute treatment of migraine in adults"</a> and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a> and  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine"</a> and  <a class="medical medical_review" href="/d/html/3352.html" rel="external">"Migraine with brainstem aura"</a> and  <a class="medical medical_review" href="/d/html/14112.html" rel="external">"Hemiplegic migraine"</a> and  <a class="medical medical_review" href="/d/html/3356.html" rel="external">"Vestibular migraine"</a> and  <a class="medical medical_review" href="/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention"</a>.)</p><p class="headingAnchor" id="H130649620"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The current state of knowledge suggests that a primary neuronal dysfunction leads to a sequence of changes intracranially and extracranially that account for migraine [<a href="#rid1">1,2</a>], including the four phases of premonitory symptoms, aura, headache, and postdrome.</p><p>The once-popular vascular theory of migraine, which suggested that migraine headache was caused by the dilatation of blood vessels while the aura of migraine resulted from vasoconstriction, is no longer considered viable [<a href="#rid3">3-5</a>]. Vasodilatation, if it occurs at all during spontaneous migraine attacks [<a href="#rid5">5</a>], is probably an epiphenomenon resulting from instability in the central neurovascular control mechanism [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H130649634"><span class="h2">Cortical spreading depression</span><span class="headingEndMark"> — </span>A causal association between migraine aura and headache is supported by evidence that both are linked to the phenomenon known as cortical spreading depression of Leão [<a href="#rid3">3,7,8</a>]. Cortical spreading depression is a self-propagating wave of neuronal and glial depolarization that spreads across the cerebral cortex. Cortical spreading depression is hypothesized to:</p><p class="bulletIndent1"><span class="glyph">●</span>Cause the aura of migraine [<a href="#rid9">9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Activate trigeminal nerve afferents [<a href="#rid10">10,11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Alter blood-brain barrier permeability by matrix metalloproteinase activation and upregulation [<a href="#rid12">12</a>]</p><p></p><p>The activation of trigeminal afferents by cortical spreading depression in turn causes inflammatory changes in the pain-sensitive meninges that generate the headache of migraine through central and peripheral reflex mechanisms [<a href="#rid13">13</a>]. The likely molecular cascade of events by which pain-sensitive trigeminal afferent neurons are activated by cortical spreading depression involves the opening of neuronal pannexin-1 megachannels and subsequent activation of caspase-1, followed by the release of the proinflammatory mediators, activation of nuclear factor kappa-B in astrocytes, and transduction of the inflammatory signal to trigeminal nerve fibers around pial vessels [<a href="#rid11">11</a>]. Thus, this pathway links cortical spreading depression, the phenomenon thought to underlie the migraine aura, to prolonged activation of trigeminal nociception, which generates the pain of the migraine headache.</p><p>It has been suggested that migraine without aura may be caused by the occurrence of cortical spreading depression in areas of the brain (eg, cerebellum) where depolarization is not consciously perceived [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H130649641"><span class="h2">Trigeminovascular system</span><span class="headingEndMark"> — </span>The pathophysiology of migraine involves activation of the trigeminovascular system, which consists of small caliber pseudounipolar sensory neurons that originate from the trigeminal ganglion and upper cervical dorsal roots [<a href="#rid15">15</a>]. These sensory neurons project to innervate large cerebral vessels, pial vessels, dura mater, and large venous sinuses. Most of the innervation of the anterior structures is via the ophthalmic division of the trigeminal nerve with a greater contribution of upper cervical roots to posterior structures.</p><p>There is convergence of the projections from the upper cervical nerve roots and the trigeminal nerve at the trigeminal nucleus caudalis [<a href="#rid16">16,17</a>]. This convergence can explain the distribution of migraine pain, which often includes anterior and posterior regions of the head and the upper neck. Once transmitted to the trigeminal nucleus caudalis by trigeminal axons, central signals can be modulated by projections from the rostral trigeminal nuclei [<a href="#rid18">18</a>], the periaqueductal gray, and the nucleus raphe magnus [<a href="#rid19">19</a>], as well as by descending cortical inhibitory systems [<a href="#rid19">19,20</a>].</p><p>From the trigeminal nucleus caudalis, fibers that are involved in the localization of pain ascend to the thalamus (mostly to the ventroposterior medial nucleus of the thalamus) and to the sensory cortex [<a href="#rid21">21</a>]. Other second-order neurons from the trigeminal nucleus caudalis project to numerous subcortical sites including the more rostral segments of the trigeminal complex [<a href="#rid22">22</a>], the reticular formation of the brain stem [<a href="#rid23">23</a>], the cerebellum [<a href="#rid24">24,25</a>], the midbrain and pontine parabrachial nuclei [<a href="#rid26">26,27</a>], the ventrobasal thalamus [<a href="#rid22">22,25,28,29</a>], the posterior thalamus [<a href="#rid30">30,31</a>], and the medial thalamus [<a href="#rid32">32</a>]. From more rostral brain stem nuclei, nociceptive information is transmitted to other brain areas (eg, limbic regions) involved in the emotional and vegetative responses to pain [<a href="#rid26">26</a>].</p><p>Stimulation of the trigeminal ganglion results in release of vasoactive neuropeptides, including substance P, calcitonin gene-related peptide (CGRP), and neurokinin A [<a href="#rid33">33</a>]. Release of these neuropeptides is associated with the process of neurogenic inflammation. The two main components of this sterile inflammatory response are vasodilation (CGRP is a potent vasodilator) and plasma protein extravasation.</p><p>Neurogenic inflammation is thought to be important in the prolongation and intensification of the pain of migraine. Elevated levels of vasoactive neuropeptides have been found in the cerebrospinal fluid of patients with chronic migraine, suggesting chronic activation of the trigeminovascular system in these patients [<a href="#rid34">34</a>]. Neurogenic inflammation may lead to the process of sensitization.</p><p class="headingAnchor" id="H203274958"><span class="h2">Sensitization</span><span class="headingEndMark"> — </span>Sensitization refers to the process in which neurons become increasingly responsive to nociceptive and non-nociceptive stimulation: response thresholds decrease, response magnitude increases, receptive fields expand, and spontaneous neuronal activity develops [<a href="#rid35">35-37</a>]. Peripheral sensitization in the primary afferent neurons and central sensitization within second-order neurons in the trigeminal nucleus caudalis and higher-order neurons in the central nervous system are thought to play a role within individual migraine attacks and, perhaps, even in the transformation of episodic migraine to chronic migraine.</p><p>Sensitization is likely responsible for many of the clinical symptoms of migraine, including the throbbing quality of the pain, the worsening of pain with coughing, bending, or sudden head movements (as is often observed during the postdrome), hyperalgesia (increased sensitivity to painful stimuli), and allodynia (pain produced by normally non-noxious stimulation).</p><p>Functional brain imaging has identified abnormalities in the ascending and descending pain pathways of patients with migraine during and in between attacks. Alterations in blood flow to the dorsal pons, anterior cingulate cortex, visual cortex, and auditory association cortex have been seen [<a href="#rid38">38,39</a>]. Patients with chronic migraine are found to have altered blood flow to the dorsal pons, anterior cingulate cortex, and cuneus [<a href="#rid40">40</a>].</p><p>Structural changes in the brain have also been found. Studies suggest that patients with migraine have increased cortical thickness in motion-processing visual areas, increased density of the periaqueductal gray and dorsolateral pons, and decreased gray matter in the anterior cingulate cortex and insula [<a href="#rid41">41,42</a>]. Increased iron levels have been identified in the periaqueductal gray of episodic and chronic migraineurs [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H130649648"><span class="h2">Role of serotonin</span><span class="headingEndMark"> — </span>Although activation at serotonin receptors is of known importance in the acute treatment of migraine, its role in the generation of migraine is unclear [<a href="#rid44">44</a>]. Some authors have suggested that serotonin (released from brainstem serotonergic nuclei) plays a role in the pathogenesis of migraine, perhaps mediated by its direct action upon the cranial vasculature, by its role in central pain control pathways, or by cerebral cortical projections of brainstem serotonergic nuclei [<a href="#rid45">45,46</a>]. Such a role for serotonin is supported by the fact that tricyclic antidepressants, which block serotonin reuptake, are effective antimigraine prophylactic agents. In contrast, however, more selective serotonin reuptake inhibitors are not very effective in migraine prevention. There is other evidence that a low serotonin state may result in a deficit in the serotonin descending pain inhibitory system, facilitating activation of the trigeminovascular nociceptive pathways in conjunction with cortical spreading depression [<a href="#rid45">45,46</a>].</p><p class="headingAnchor" id="H130649655"><span class="h2">Role of calcitonin gene-related peptide</span><span class="headingEndMark"> — </span>The calcitonin gene-related peptide has a key role in migraine pathophysiology [<a href="#rid47">47</a>]. CGRP is a 37 amino acid neuropeptide that is expressed in trigeminal ganglia nerves and is a potent vasodilator of cerebral and dural vessels [<a href="#rid48">48</a>]. CGRP appears to mediate trigeminovascular pain transmission from intracranial vessels to the central nervous system, as well as the vasodilatory component of neurogenic inflammation [<a href="#rid47">47</a>]. Stimulation of the trigeminal ganglion induces the release of CGRP [<a href="#rid33">33</a>], and CGRP infusion can trigger a migraine attack in patients with migraine [<a href="#rid49">49</a>]. One study found elevation of CGRP levels in external jugular venous blood during migraine attacks [<a href="#rid50">50</a>]. Another found that elevated CGRP levels were normalized in patients with migraine following administration of the serotonin 1b/1d receptor agonist <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> [<a href="#rid51">51</a>], suggesting that triptans may act to control migraine at least in part by blocking the release of CGRP. These and other data have established that CGRP release plays an important modulatory role in migraine headache [<a href="#rid47">47</a>].</p><p>The use of CGRP antagonists for migraine treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'CGRP antagonists'</a> and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'CGRP antagonists'</a>.)</p><p class="headingAnchor" id="H2643999481"><span class="h2">Right-to-left cardiac shunt</span><span class="headingEndMark"> — </span>Migraine with aura has been linked to right-to-left cardiac shunts, usually in the setting of a patent foramen ovale (PFO) or, much less often, an atrial septal defect (ASD) [<a href="#rid52">52-54</a>] or pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/1418.html" rel="external">"Clinical manifestations and diagnosis of atrial septal defects in adults"</a> and  <a class="medical medical_review" href="/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p>Evidence regarding the association of migraine with PFO is conflicting.</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study of 1101 stroke-free subjects (mean age 69 years) from the NOMAS cohort who were evaluated for PFO using transthoracic echocardiography with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> contrast and provocative maneuvers, there was no significant difference in the prevalence of PFO among subjects who had migraine compared with those who did not have migraine (14.6 versus 15.0 percent) [<a href="#rid56">56</a>]. The presence of PFO was not associated with an increased prevalence of migraine (odds ratio [OR] 1.01, 95% CI 0.63-1.61) or an increased prevalence of migraine with aura (OR 1.01, 95% CI 0.71-1.69) compared with no migraine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of case-control studies published in 2008 concluded that migraine with aura (but not without aura) is more common in patients with PFO than in the general population and that PFO is more prevalent in patients who have migraine with aura than in the general population [<a href="#rid57">57</a>].</p><p></p><p>While definitive conclusions are not yet possible, the population-based NOMAS study provides high-quality observational evidence that PFO is not associated with migraine [<a href="#rid58">58</a>]. In contrast, the association of PFO with migraine in the systematic review is supported by low or low to moderate quality evidence [<a href="#rid57">57</a>].</p><p>The mechanism of any possible association between right-to-left cardiac shunt and migraine is not known. One theory is that a genetic influence might predispose some patients to a higher risk of developing both atrial septal abnormalities and migraine [<a href="#rid59">59</a>]. Other theories focus on the shunt pathway. As examples, one hypothesis is that the venous circulation contains vasoactive substances capable of triggering migraine; these are normally inactivated in the lungs but gain access to the cranial circulation in the presence of a right-to-left shunt [<a href="#rid60">60</a>]. Another hypothesis is that the existence of the shunt provides a pathway for paradoxical embolism and subsequent cerebral ischemia, which in turn triggers migraine. (See  <a class="medical medical_review" href="/d/html/1092.html" rel="external">"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults"</a>.)</p><p class="headingAnchor" id="H130650647"><span class="h1">GENETIC BASIS</span><span class="headingEndMark"> — </span>Migraine is a syndromic disorder of the brain that is in most instances inherited. As with most common diseases, the genetic basis of migraine is likely to be complex and in some individuals may be based on the additive effect of more than one genetic source. Individuals prone to migraine have a genetic threshold that renders them susceptible to an acute migraine attack depending upon the balance between excitation and inhibition at various levels of the nervous system. Subtle abnormalities, involving membrane channels, receptor families, and enzyme systems have been linked to migraine in certain groups and individuals.</p><p>The importance of inheritance in migraine has long been recognized [<a href="#rid61">61</a>]. One early general population-based study found that the risk of migraine in relatives of patients with migraine was three times greater than that of relatives of non-migraine control subjects [<a href="#rid62">62</a>]. However segregation analysis does not identify any single Mendelian pattern of inheritance in the common forms of migraine [<a href="#rid63">63</a>]. Large national registry-based twin studies have confirmed a consistently higher concordance of migraine in monozygotic twins versus dizygotic twins. In one such study, using a polygenic multifactorial model, researchers estimated that inheritance accounts for 40 to 50 percent of an individual's susceptibility to migraine [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H130650973"><span class="h2">Genetics of the common forms of migraine</span><span class="headingEndMark"> — </span>The genetic basis of the common forms of migraine (migraine with aura and migraine without aura) has not been clarified despite increasing research. A number of candidate genes have been linked with migraine, a list that includes the <em>KCNK18</em> gene that encodes for TRESK, a two-pore domain potassium channel [<a href="#rid65">65</a>], and the <em>CSNK1D</em> gene, which encodes casein kinase I isoform delta [<a href="#rid66">66</a>]. However, the findings of gene studies in migraine generally have not been replicated in subsequent reports. As an example, a systematic reevaluation of 27 promising candidate migraine genes in a large dataset compiled from genome-wide association studies (GWAS), with over 5175 patients with migraine and 13,972 control subjects, found that none of the candidate genes reached the threshold for statistical significance [<a href="#rid67">67</a>]. Thus, it is still uncertain which candidate loci and genes are truly implicated in the pathogenesis of migraine.</p><p>The common forms of migraine are likely to be complex genetic disorders, meaning that multiple genes at different genomic sites act in tandem with environmental factors to confer both the susceptibility to and the characteristics of the disease in affected individuals. One possible explanation for the lack of replication in genetic studies of migraine is that a few gene polymorphisms are frequently tested for association in relatively small populations in which only a portion of the subjects have migraine that arises from the studied variant, while the migraine in other case subjects has a different basis. This would tend to lower the power of many of these studies to detect a significant difference in the case subjects compared with the non-migraine control subjects. The eventual identification of the genes that underlie migraine in an individual patient is extremely important, as it may be predictive of the type of prophylactic treatment to which the patient will respond.</p><p class="headingAnchor" id="H130650654"><span class="h2">Familial hemiplegic migraine</span><span class="headingEndMark"> — </span>Hemiplegic migraine may occur either in families or only in one individual (sporadic). The first three types of familial hemiplegic migraine (FHM) are channelopathies. FHM1 is caused by variants of the <em>CACNA1A</em> gene, FHM2 by variants of the <em>ATP1A2</em> gene, and FHM3 by variants of the <em>SCN1A</em> gene. Variants of the <em>PRRT2</em> gene also cause some cases of familial hemiplegic migraine. The known types of familial hemiplegic migraine account for only a small proportion of cases. (See  <a class="medical medical_review" href="/d/html/14112.html" rel="external">"Hemiplegic migraine", section on 'Familial hemiplegic migraine'</a>.)</p><p class="headingAnchor" id="H21674074"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Migraine is a common disorder that affects 12 to 15 percent of the general population [<a href="#rid68">68,69</a>]. It is more frequent in females than in males, with attacks occurring in up to 17 percent of females and 6 percent of males each year [<a href="#rid70">70,71</a>]. Migraine without aura is the most common type, accounting for approximately 75 percent of cases.</p><p>Migraine is most common in those aged 30 to 39, an age span in which prevalence in males and females reaches 7 and 24 percent, respectively  (<a class="graphic graphic_figure graphicRef57550" href="/d/graphic/57550.html" rel="external">figure 1</a>) [<a href="#rid71">71</a>]. Migraine also tends to run in families. (See <a class="local">'Genetic basis'</a> above.)</p><p>Migraine is a major cause of disability and ranked second after low back pain worldwide among all diseases with respect to years of life lived with disability [<a href="#rid69">69,72</a>].</p><p>Data from several retrospective nationwide cohort studies in Taiwan, all from the same group of investigators, suggest that migraine is a potential risk factor for Bell's palsy, sensorineural hearing loss, and oculomotor cranial nerve palsies [<a href="#rid73">73-75</a>]; independent reports are needed to confirm these associations.</p><p class="headingAnchor" id="H3779187741"><span class="h1">PRECIPITATING AND EXACERBATING FACTORS</span><span class="headingEndMark"> — </span>Several environmental and dietary stimuli have been reported to trigger migraine attacks. An evidence-based review concluded that stress, menstruation, visual stimuli, weather changes, nitrates, fasting, and wine were probable migraine trigger factors, while sleep disturbances and aspartame were possible migraine triggers [<a href="#rid76">76</a>]. All of the probable and possible migraine triggers except aspartame were also general headache triggers. There was evidence that monosodium glutamate was a general headache trigger but unproven as a migraine trigger. Smoking, odors, chocolate, and tyramine were unproven as triggers of migraine or general headache.</p><p>In a retrospective study of 1750 patients with migraine, approximately 75 percent reported at least one trigger of acute migraine attacks [<a href="#rid77">77</a>]. In order of descending frequency these included:</p><p class="bulletIndent1"><span class="glyph">●</span>Emotional stress (80 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hormones in females (65 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Not eating (57 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Weather (53 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disturbances (50 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Odors (44 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Neck pain (38 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Lights (38 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol (38 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Smoke (36 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Sleeping late (32 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Heat (30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Food (27 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise (22 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual activity (5 percent)</p><p></p><p>Many alcoholic beverages can trigger migraine, but red wine appears to be the most common trigger in cross-sectional studies [<a href="#rid78">78,79</a>]. Flavonoid phenols, sulfites, or other compounds have been posited to account for "red wine headache" amongst patients reporting this trigger [<a href="#rid80">80,81</a>]. Additional factors may be implicated, as white wine, spirits, and other alcoholic beverages are triggers for other patients.</p><p>Sleep disturbances and migraine are often comorbid, but both disorders are fairly common in the general population and their co-occurrence could be coincidental [<a href="#rid82">82-85</a>]. Nevertheless, the study cited above suggests that sleep disorders can exacerbate migraine [<a href="#rid77">77</a>]. In addition, poor sleep quality has been associated with increased migraine headache frequency and disability [<a href="#rid86">86,87</a>]. Obesity also has been associated with an increased frequency and severity of migraine [<a href="#rid88">88-90</a>]. Migraine headaches are often worsened by rapid head motion, sneezing, straining at stool, constant movement, or physical exertion.</p><p class="headingAnchor" id="H21674085"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Migraine is a disorder of recurrent attacks. The attacks unfold through a cascade of events that occur over the course of several hours to days. A typical migraine attack progresses through four phases: the prodrome, the aura, the headache, and the postdrome [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H203275048"><span class="h2">Migraine prodrome</span><span class="headingEndMark"> — </span>The prodrome occurs in up to 77 percent of patients with migraine and consists of affective or vegetative symptoms that appear 24 to 48 hours prior to the onset of headache [<a href="#rid92">92,93</a>]. Frequently reported prodromal symptoms include increased yawning, euphoria, depression, irritability, food cravings, constipation, and neck stiffness.</p><p class="headingAnchor" id="H203275055"><span class="h2">Migraine aura</span><span class="headingEndMark"> — </span>About 25 percent of people with migraines experience one or more focal neurologic symptoms in the second phase, called the migraine aura. Traditional teaching is that migraine aura usually precedes the headache. However, prospective data suggest that most patients with migraine experience headache during the aura phase [<a href="#rid94">94</a>].</p><p>Typical migraine auras are characterized by gradual development, duration no longer than one hour, a mix of positive and negative features, and complete reversibility [<a href="#rid95">95</a>]. Positive symptoms indicate active discharge from central nervous system neurons. Typical positive symptoms can be visual (eg, bright lines, shapes, objects), auditory (eg, tinnitus, noises, music), somatosensory (eg, burning, pain, paresthesia), or motor (eg, jerking or repetitive rhythmic movements). Negative symptoms indicate an absence or loss of function, such as loss of vision, hearing, feeling, or ability to move a part of the body. Auras are most often visual but can also be sensory, verbal, or motor disturbances.</p><p>The aura of migraine usually develops gradually over more than five minutes. Less often, the aura develops more acutely (ie, in less than five minutes). The acute onset of aura makes confusion with a transient ischemic attack (TIA) or stroke more likely. In one case series, four patients (2 percent) had exclusively acute-onset visual aura [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H2109237351"><span class="h3">Visual aura</span><span class="headingEndMark"> — </span>A visual aura classically begins as a small area of visual loss often just lateral to the point of visual fixation. It may either appear as a bright spot or as an area of visual loss. Over the following five minutes to one hour, the visual disturbance expands to involve a quadrant or hemifield of vision. Along the expanding margin, geometric shapes or zigzagging lines often appear. The shapes account for one of the common names for aura, the "fortification spectrum," because of the resemblance of the aura to the walls of a medieval fortress. The positive visual phenomena may assume a sickle or C-shape, expanding over time toward the peripheral visual field, leaving a scotoma or area of complete visual loss in their wake. As the aura moves off into the peripheral visual field, it often assumes a shimmering or scintillating quality. As the aura resolves, vision usually returns first to the areas of central vision initially affected by the aura [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/d/html/5255.html" rel="external">"Approach to the patient with visual hallucinations", section on 'Migraine aura'</a>.)</p><p class="headingAnchor" id="H2278590261"><span class="h3">Sensory aura</span><span class="headingEndMark"> — </span>The sensory aura is also common and typically follows the visual aura within minutes, although it may also occur without the visual aura. A sensory aura usually begins as a tingling in one limb or on one side of the face. As the tingling sensation migrates across one side of the face or down the limb, numbness is left in its wake that may last up to an hour. The sensory aura may also move inside the mouth, affecting the buccal mucosa and half the tongue. The slow spread of positive symptoms (scintillations or tingling) followed by negative symptoms (scotoma or numbness) is quite characteristic of migraine aura and is not typical for an ischemic event [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H1718091796"><span class="h3">Language aura</span><span class="headingEndMark"> — </span>Less common than the visual and sensory auras is the language or dysphasic aura. Language auras cause transient problems that may run the gamut from mild wording difficulties to frank dysphasia with paraphasic errors.</p><p class="headingAnchor" id="H972408822"><span class="h3">Motor aura</span><span class="headingEndMark"> — </span>In the rarest of auras, motor aura, the limbs and possibly the face on one side of the body become weak. Because of information related to the genetic basis of the motor aura, it has been separated from the other forms of aura and classified as hemiplegic migraine (see  <a class="medical medical_review" href="/d/html/14112.html" rel="external">"Hemiplegic migraine"</a>). The aura symptoms may occur either singly or in sequence, but they do not generally occur simultaneously.</p><p class="headingAnchor" id="H1834790112"><span class="h3">Aura without headache</span><span class="headingEndMark"> — </span>Some patients may experience aura without an associated headache. Migraine aura without headache (also known as migraine equivalent and acephalgic migraine) manifests as isolated aura unaccompanied by headache. In a Danish case study, 38 percent of patients reported having both attacks of migraine aura without headache as well as migraine aura with headache, and 4 percent had exclusively migraine aura without headache [<a href="#rid96">96</a>]. Auras without headache may be confused with transient ischemic attacks, especially when they first present in older patients as late-life migraine accompaniments, which are described in the next section.</p><p class="headingAnchor" id="H2924906008"><span class="h3">Late-life migraine accompaniments</span><span class="headingEndMark"> — </span>Late-life migraine accompaniments are symptoms related to the onset after the age of 50 years of migraine aura without headache [<a href="#rid98">98,99</a>]. The most common symptoms are visual auras, followed by sensory auras (paresthesia), speech disturbances, and motor auras (weakness or paralysis). The most common presentation is gradual evolution of aura symptoms with spread of transient neurologic deficits over several minutes and serial progression from one symptom to another.</p><p class="headingAnchor" id="H203275062"><span class="h2">Migraine headache</span><span class="headingEndMark"> — </span>The headache of migraine is often but not always unilateral and tends to have a throbbing or pulsatile quality, especially as the intensity increases. As the attack severity increases over the course of one to several hours, patients frequently experience nausea and sometimes vomiting. Many individuals report photophobia or phonophobia during attacks, leading such patients with migraine to seek relief by lying down in a darkened, quiet room. Additional migrainous features such as osmophobia and cutaneous allodynia (see <a class="local">'Cutaneous allodynia'</a> below) may occur during attacks [<a href="#rid91">91,100-102</a>].</p><p>In adults, an untreated headache can last as little as four hours and as long as several days. Many attacks resolve in sleep.</p><p class="headingAnchor" id="H203275069"><span class="h2">Migraine postdrome</span><span class="headingEndMark"> — </span>Once the spontaneous throbbing of the headache resolves, the patient may experience a postdromal phase, during which sudden head movement transiently causes pain in the location of the antecedent headache. During the postdrome, patients often feel drained or exhausted, although some report a feeling of mild elation or euphoria [<a href="#rid103">103-105</a>].</p><p class="headingAnchor" id="H21674099"><span class="h2">Cutaneous allodynia</span><span class="headingEndMark"> — </span>Cutaneous allodynia is the perception of pain produced by innocuous stimulation of normal skin and may result from sensitization of central pain pathways in migraine [<a href="#rid106">106</a>]. (See <a class="local">'Sensitization'</a> above.)</p><p>As examples, brushing hair, touching the scalp, shaving, or wearing contact lenses may trigger allodynic symptoms of pain during migraine. Additional symptoms include tenderness or difficulty resting on the allodynic side.</p><p>Cutaneous allodynia occurs frequently with migraine, and it may occur even in the absence of headache. In one study, allodynia was reported by 62 percent of 11,094 patients with migraine who completed a questionnaire [<a href="#rid107">107</a>]. In an earlier survey of 157 patients with migraine and allodynia, the most common locations of allodynia were pure cephalic and cephalic plus extracephalic, occurring in 85 and 34 percent, respectively [<a href="#rid108">108</a>]. Pure extracephalic allodynia occurred in 15 percent. Scalp allodynia was ipsilateral to the predominant headache side in the majority of cases and occurred at the height of headache. Trunk allodynia occurred in a few patients.</p><p>The true frequency of allodynia appears to be even higher when assessed by measurement of mechanical and thermal pain thresholds of skin. In a case series of 42 subjects with migraine, 79 percent reported cutaneous allodynia on the head ipsilateral to the migraine pain by quantitative sensitivity testing, and 67 percent experienced cutaneous allodynia in additional regions such as the contralateral head or extracephalic sites [<a href="#rid106">106</a>]. The actual percentage of people with migraine spontaneously reporting cutaneous allodynia is lower.</p><p>Severe or persistent cutaneous allodynia may respond to abortive and prophylactic therapy. However, existing data suggest that abortive therapy with triptans is less effective once cutaneous allodynia develops. (See  <a class="medical medical_review" href="/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'Triptans'</a>.)</p><p class="headingAnchor" id="H229739406"><span class="h1">MIGRAINE SUBTYPES</span><span class="headingEndMark"> — </span>Although there are numerous references in the medical literature to unexplained neurologic symptoms that are called migraine variant or migraine equivalent, most of these are probably not related to migraine. Nevertheless, there are several well-characterized subtypes of migraine, including migraine with brainstem aura, hemiplegic migraine, retinal migraine, vestibular migraine, menstrual migraine, and chronic migraine. Complications of migraine are characterized by prolonged symptoms or, rarely, with infarction or seizures (ie, status migrainosus, persistent aura without infarction, migrainous infarction, and migraine aura-triggered seizure) [<a href="#rid95">95</a>].</p><p>Recurrent painful ophthalmoplegic neuropathy, previously termed ophthalmoplegic migraine, is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3355.html" rel="external">"Overview of craniofacial pain", section on 'Recurrent painful ophthalmoplegic neuropathy'</a>.)</p><p class="headingAnchor" id="H222097300"><span class="h2">Migraine with brainstem aura</span><span class="headingEndMark"> — </span>Migraine with brainstem aura, reviewed here briefly and discussed in detail elsewhere (see  <a class="medical medical_review" href="/d/html/3352.html" rel="external">"Migraine with brainstem aura"</a>), is an uncommon form of migraine with aura wherein the primary signs and symptoms are referable to the brainstem without weakness. Migraine with brainstem aura was previously called basilar-type migraine. It occurs more often in females than in males. Onset is usually between ages 7 and 20. The auras consist of some combination of vertigo, dysarthria, tinnitus, diplopia, ataxia, decreased level of consciousness, and hypacusis. Attacks nearly always include two or more brainstem-related aura symptoms  (<a class="graphic graphic_table graphicRef73674" href="/d/graphic/73674.html" rel="external">table 1</a>). Attacks may evolve to more typical common forms of migraine with age.</p><p>The occurrence of decreased level of consciousness followed by headache sometimes results in diagnostic difficulty. It is important to remember that migraine with brainstem aura is rare and that there must be another brainstem symptom in addition to decreased consciousness to make the diagnosis. In the absence of a second brainstem-localizing symptom, other causes of unexplained loss of consciousness such as seizure and cardiogenic syncope must be considered and appropriately investigated. Migraine with brainstem aura should be diagnosed only when weakness is absent, since a number of patients with familial hemiplegic migraine have brainstem symptoms. (See  <a class="medical medical_review" href="/d/html/3352.html" rel="external">"Migraine with brainstem aura"</a> and  <a class="medical medical_review" href="/d/html/14112.html" rel="external">"Hemiplegic migraine"</a>.)</p><p class="headingAnchor" id="H140723664"><span class="h2">Hemiplegic migraine</span><span class="headingEndMark"> — </span>The primary feature that separates hemiplegic migraine from other types of migraine with aura is the presence of motor weakness as a manifestation of aura in at least some attacks. In addition to motor weakness during the aura phase, which is typically unilateral, the manifestations of hemiplegic migraine attacks may variously include severe headache, scintillating scotoma, visual field defect, numbness, paresthesia, aphasia, fever, lethargy, coma, and seizures. Hemiplegic migraine may occur either in families or only in one individual (sporadic). (See  <a class="medical medical_review" href="/d/html/14112.html" rel="external">"Hemiplegic migraine"</a>.)</p><p class="headingAnchor" id="H222097314"><span class="h2">Retinal migraine</span><span class="headingEndMark"> — </span>Retinal migraine is a rare condition that is characterized by repeated attacks of monocular scotomata or blindness lasting less than one hour, associated with or followed by headache. The International Headache Society prefers the term retinal migraine [<a href="#rid95">95</a>], but ocular migraine has been suggested as a more precise term, since both retinal and ciliary circulations may be involved [<a href="#rid109">109</a>]. Occasionally, the onset may be abrupt and difficult to distinguish from amaurosis fugax [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/d/html/5245.html" rel="external">"Amaurosis fugax (transient monocular or binocular visual loss)"</a>.)</p><p>Irreversible visual loss may be a complication of retinal migraine, although the incidence is uncertain. In one of the largest studies to date that reported 6 new cases and reviewed 40 from the literature, permanent visual loss was eventually present in 20 patients (43 percent) [<a href="#rid110">110</a>]. No predictors of irreversible visual loss could be identified, and no consistent pattern of visual loss was observed among these patients. However, permanent visual loss may be less frequent than suggested by these data, since it is likely that cases with such a major complication are more apt to be identified and to be reported (ie, reporting bias).</p><p>The authors speculated that permanent visual loss resulting from retinal migraine may be a type of migrainous infarction, leading them to suggest the use of prophylactic migraine therapy with antiepileptic or tricyclic medications for patients with this condition [<a href="#rid110">110</a>]. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a> and  <a class="medical medical_review" href="/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention", section on 'Diagnostic criteria'</a>.)</p><p class="headingAnchor" id="H140723703"><span class="h2">Chronic migraine</span><span class="headingEndMark"> — </span>Chronic migraine is defined as headache occurring 15 or more days a month for more than three months, which has the features of migraine headache on at least eight days a month [<a href="#rid95">95</a>]. The current classification scheme recognizes chronic migraine as a separate subform because it may be impossible to distinguish the individual episodes of headache in patients with such frequent or continuous headaches. Furthermore, the characteristics of the headache may change from day to day or even within the same day. (See  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine"</a>.)</p><p class="headingAnchor" id="H140724091"><span class="h2">Complications of migraine</span><span class="headingEndMark"> — </span>Complications of migraine are characterized by attacks associated with prolonged symptoms or, rarely, with infarction or seizures. Prolonged symptoms may last for the entire headache, for several days or weeks, or in some cases leave a permanent neurologic deficit.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Status migrainosus</strong> is a debilitating migraine attack lasting for more than 72 hours. The median attack duration is approximately five days. The incidence rate of status migrainosus is 27 per 100,000 with a peak incidence in the fifth decade [<a href="#rid111">111</a>]. It is more common among females than males and may occur in patients with migraine either with or without aura.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent aura without infarction</strong> is defined by aura symptoms persisting for one week or more with no evidence of infarction on neuroimaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migrainous infarction</strong> is defined by a migraine attack, occurring in a patient with migraine with aura, in which one or more aura symptoms persist for more than one hour and neuroimaging shows an infarction in a relevant brain area. (See  <a class="medical medical_review" href="/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention", section on 'Migraine-associated ischemic stroke'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migraine aura-triggered seizure</strong> is a seizure triggered by an attack of migraine with aura.</p><p></p><p class="headingAnchor" id="H222097335"><span class="h2">Vestibular migraine</span><span class="headingEndMark"> — </span>Vestibular migraine (also called migrainous vertigo) is reviewed briefly here and discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3356.html" rel="external">"Vestibular migraine"</a>.)</p><p>Vestibular migraine is a term used to describe episodic vertigo in patients with a history of migraines or with other clinical features of migraine (photophobia, phonophobia, visual aura, etc). The association of headache with vertigo is variable, even in individual patients. There are no confirmatory tests for vestibular migraine  (<a class="graphic graphic_table graphicRef75023" href="/d/graphic/75023.html" rel="external">table 2</a>). Other disorders, specifically Meniere disease and structural and vascular brainstem disease, must be excluded in most patients.</p><p class="headingAnchor" id="H140723897"><span class="h2">Estrogen-associated (menstrual) migraine</span><span class="headingEndMark"> — </span>Menstrual migraine (also called menstrually associated migraine or catamenial migraine) is defined as migraine headache that occurs in close temporal relationship to the onset of menstruation; this time period usually encompasses two days before through three days after the onset of menstrual bleeding [<a href="#rid95">95</a>]. Females with menstrual migraine may also have migraine at other times during the month. (See  <a class="medical medical_review" href="/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine"</a>.)</p><p>The treatment of menstrual migraine is discussed separately. (See  <a class="medical medical_review" href="/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine", section on 'Treatment progression'</a>.)</p><p class="headingAnchor" id="H203275744"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of migraine is a clinical task and is based upon a compatible history, physical examination, and fulfillment of the diagnostic criteria listed below. There are no diagnostic tests specific for migraine.</p><p>While the features of migraine and tension headache overlap, the clinical features that appear to be most predictive of migraine include nausea, photophobia, phonophobia, and exacerbation by physical activity [<a href="#rid112">112</a>]. Food triggers are also more common with migraine than tension-type headache. (See  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H21674113"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The International Classification of Headache Disorders, 3<sup>rd</sup> edition (ICHD-3) specifies diagnostic criteria for migraine  (<a class="graphic graphic_table graphicRef50876" href="/d/graphic/50876.html" rel="external">table 3</a>) [<a href="#rid95">95</a>].</p><p>The ICHD-3 criteria for <strong>migraine without aura</strong> are the following [<a href="#rid95">95</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>(A) At least five attacks fulfilling criteria B through D</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(B) Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(C) Headache has at least two of the following characteristics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unilateral location</p><p class="bulletIndent2"><span class="glyph">•</span>Pulsating quality</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate or severe pain intensity</p><p class="bulletIndent2"><span class="glyph">•</span>Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(D) During headache, at least one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nausea, vomiting, or both</p><p class="bulletIndent2"><span class="glyph">•</span>Photophobia and phonophobia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(E) Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>The ICHD-3 criteria for <strong>migraine with aura</strong> are as follows [<a href="#rid95">95</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>(A) At least two attacks fulfilling criterion B and C</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(B) One or more of the following fully reversible aura symptoms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Visual</p><p class="bulletIndent2"><span class="glyph">•</span>Sensory</p><p class="bulletIndent2"><span class="glyph">•</span>Speech and/or language</p><p class="bulletIndent2"><span class="glyph">•</span>Motor</p><p class="bulletIndent2"><span class="glyph">•</span>Brainstem</p><p class="bulletIndent2"><span class="glyph">•</span>Retinal</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(C) At least three of the following six characteristics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one aura symptom spreads gradually over ≥5 minutes</p><p class="bulletIndent2"><span class="glyph">•</span>Two or more symptoms occur in succession</p><p class="bulletIndent2"><span class="glyph">•</span>Each individual aura symptom lasts 5 to 60 minutes</p><p class="bulletIndent2"><span class="glyph">•</span>At least one aura symptom is unilateral</p><p class="bulletIndent2"><span class="glyph">•</span>At least one aura symptom is positive</p><p class="bulletIndent2"><span class="glyph">•</span>The aura is accompanied, or followed within 60 minutes, by headache</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(D) Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>The ICHD-3 criteria for <strong>migraine with typical aura</strong> require attacks fulfilling criteria for migraine with aura and auras consisting of visual, sensory, and/or speech/language symptoms but no motor, brainstem, or retinal symptoms [<a href="#rid95">95</a>]. When the aura includes motor weakness, the disorder is diagnosed as hemiplegic migraine. When the aura symptoms arise from the brainstem, the disorder is diagnosed as migraine with brainstem aura. When the aura involves documented monocular visual phenomena (documented by clinical visual field examination or patient drawing of a monocular field defect), the disorder is diagnosed as retinal migraine.</p><p class="headingAnchor" id="H222096759"><span class="h2">Diagnostic testing</span><span class="headingEndMark"> — </span>Neuroimaging is not necessary in most patients with migraine. Evidence-based guidelines issued by the American Academy of Neurology suggest considering neuroimaging in the following patients with non-acute headache [<a href="#rid113">113</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with an unexplained abnormal finding on neurologic examination</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with atypical headache features or headaches that do not fulfill the strict definition of migraine or other primary headache disorder (or have some additional risk factor, such as immune deficiency)</p><p></p><p>Patients with sudden, severe headache also need neuroimaging because of the suspicion of subarachnoid hemorrhage. (See  <a class="medical medical_review" href="/d/html/3349.html" rel="external">"Evaluation of headache in adults", section on 'Indications for imaging'</a>.)</p><p>The following clinical situations may warrant neuroimaging [<a href="#rid114">114,115</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The "first or worst" headache</p><p class="bulletIndent1"><span class="glyph">●</span>Recent significant change in the pattern, frequency, or severity of headaches</p><p class="bulletIndent1"><span class="glyph">●</span>New or unexplained neurologic symptoms or signs</p><p class="bulletIndent1"><span class="glyph">●</span>Headache always on the same side</p><p class="bulletIndent1"><span class="glyph">●</span>Headaches not responding to treatment</p><p class="bulletIndent1"><span class="glyph">●</span>New-onset headaches after age 50 years</p><p class="bulletIndent1"><span class="glyph">●</span>New-onset headaches in patients with cancer or HIV infection</p><p class="bulletIndent1"><span class="glyph">●</span>Associated symptoms and signs such as fever, stiff neck, papilledema, cognitive impairment, or personality change</p><p></p><p>Head computed tomography (CT) scan (without and with contrast) is sufficient in many patients when neuroimaging is deemed necessary [<a href="#rid116">116</a>]. Magnetic resonance imaging (MRI) is indicated when posterior fossa lesions or cerebrospinal fluid (CSF) leak are suspected. Magnetic resonance angiography (MRA) and magnetic resonance venography (MRV) are indicated when arterial or venous lesions, respectively, are considered in the differential diagnosis.</p><p>No other diagnostic tests are typically necessary in patients with suspected migraine.</p><p class="headingAnchor" id="H27213256"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of migraine headache is broad and includes other types of primary headaches, such as tension-type headache and trigeminal autonomic cephalalgias such as cluster headache  (<a class="graphic graphic_table graphicRef68064" href="/d/graphic/68064.html" rel="external">table 4</a>), and secondary headaches (ie, headache caused by another disorder such as head or neck trauma, cerebrovascular disorders, intracranial lesions, disorders of face, skull, or adjacent structures, or infection).</p><p>The differential diagnosis for migraine aura includes transient ischemic attack (TIA), seizure, syncope, and vestibular disorders. Useful features for distinguishing these various types of transient neurologic attacks include the nature of the symptoms, their progression, duration and timing, associated symptoms during and after the attacks  (<a class="graphic graphic_table graphicRef111740" href="/d/graphic/111740.html" rel="external">table 5</a>), and presence of focal or nonfocal symptoms. The symptoms of TIA and migraine are fully reversible, and neuroimaging is often unrevealing in both conditions. However, both a TIA and an ischemic stroke typically have a sudden onset of symptoms rather than a gradual progressive spread of one aura symptom after another. Ischemic events are also less likely to have positive symptoms such as visual scintillations or paresthesia and are less likely to have migrainous symptoms such as nausea, vomiting, photophobia, and phonophobia. (See  <a class="medical medical_review" href="/d/html/1137.html" rel="external">"Differential diagnosis of transient ischemic attack and acute stroke"</a>.)</p><p>An exception might be brain ischemia caused by cervical artery dissection, which can have both a progressive spread of symptoms and some migrainous features. (See  <a class="medical medical_review" href="/d/html/14082.html" rel="external">"Cerebral and cervical artery dissection: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H913905414"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H2815499"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/112403.html" rel="external">"Patient education: Migraines in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15440.html" rel="external">"Patient education: Headaches in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/734.html" rel="external">"Patient education: Migraines in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/719.html" rel="external">"Patient education: Headache causes and diagnosis in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13436872"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Cortical spreading depression is hypothesized to cause the aura of migraine, activate trigeminal nerve afferents, and alter blood-brain barrier permeability. Activation of the trigeminovascular system plays a central role in the pathophysiology of migraine, including the onset of neurogenic inflammation, which is linked to the pain of migraine. Sensitization, a process in which neurons become increasingly responsive to nociceptive and non-nociceptive stimulation, is likely responsible for many of the clinical symptoms of migraine. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1">The genetic basis of the common forms of migraine is likely complex. The <em>KCNK18</em> and <em>CSNK1D</em> genes have been implicated in the pathogenesis of migraine with aura. Familial hemiplegic migraine is associated with pathologic variants in four genes, three of which encode for transmembrane ion channels. (See <a class="local">'Genetic basis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Migraine is a common condition that affects up to 12 percent of the general population. Migraine is most common in those aged 30 to 39, an age span in which prevalence in males and females reaches 7 and 24 percent, respectively  (<a class="graphic graphic_figure graphicRef57550" href="/d/graphic/57550.html" rel="external">figure 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precipitating factors</strong> – Migraine trigger factors may include stress, menstruation, visual stimuli, weather changes, nitrates, fasting, wine, sleep disturbances, and aspartame, among others. (See <a class="local">'Precipitating and exacerbating factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Migraine is a disorder of recurrent attacks. The attacks unfold through a cascade of events that occur over the course of several hours to days. A typical migraine attack progresses through four phases: the prodrome, the aura, the headache, and the postdrome. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The prodrome consists of affective or vegetative symptoms that appear 24 to 48 hours prior to the onset of headache. (See <a class="local">'Migraine prodrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>About 25 percent of people with migraines experience one or more focal neurologic symptoms in the second phase, called the migraine aura. Auras are most often visual but can also be sensory, verbal, or motor disturbances. (See <a class="local">'Migraine aura'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The headache of migraine is often but not always unilateral and tends to have a throbbing or pulsatile quality. Accompanying features may include nausea, vomiting, photophobia, or phonophobia during attacks. (See <a class="local">'Migraine headache'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migraine subtypes</strong> – Subtypes of migraine include migraine with brainstem aura, hemiplegic migraine, retinal migraine, vestibular migraine, menstrual migraine, and chronic migraine. (See <a class="local">'Migraine subtypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and evaluation</strong> – The diagnosis of migraine is a clinical task and is based upon a compatible history, physical examination, and fulfillment of the diagnostic criteria  (<a class="graphic graphic_table graphicRef50876" href="/d/graphic/50876.html" rel="external">table 3</a>). Neuroimaging is not necessary in most patients. However, we recommend neuroimaging for patients with suspected migraine or nonacute headache who have either an unexplained abnormal finding on neurologic examination, atypical headache features, headaches that do not fulfill the strict definition of migraine or other primary headache disorder, or some additional risk factor for secondary headache, such as immune deficiency. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of migraine headache is broad and includes other types of primary headaches  (<a class="graphic graphic_table graphicRef68064" href="/d/graphic/68064.html" rel="external">table 4</a>) and secondary headaches as well as transient neurologic attacks  (<a class="graphic graphic_table graphicRef111740" href="/d/graphic/111740.html" rel="external">table 5</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1530286007"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ashraf Sabahat, MD and Zahid H Bajwa, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cutrer FM. Pathophysiology of migraine. Semin Neurol 2006; 26:171.</a></li><li><a class="nounderline abstract_t">Ashina M. Migraine. N Engl J Med 2020; 383:1866.</a></li><li><a class="nounderline abstract_t">Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009; 65:491.</a></li><li><a class="nounderline abstract_t">Charles A. Vasodilation out of the picture as a cause of migraine headache. Lancet Neurol 2013; 12:419.</a></li><li><a class="nounderline abstract_t">Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013; 12:454.</a></li><li><a class="nounderline abstract_t">Welch KM. Drug therapy of migraine. N Engl J Med 1993; 329:1476.</a></li><li><a class="nounderline abstract_t">Leão AA. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7:359.</a></li><li><a class="nounderline abstract_t">Leão AA. Pial circulation and spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7:391.</a></li><li><a class="nounderline abstract_t">Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 2001; 98:4687.</a></li><li><a class="nounderline abstract_t">Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993; 13:1167.</a></li><li><a class="nounderline abstract_t">Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 2013; 339:1092.</a></li><li><a class="nounderline abstract_t">Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004; 113:1447.</a></li><li><a class="nounderline abstract_t">Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8:136.</a></li><li><a class="nounderline abstract_t">Takano T, Nedergaard M. Deciphering migraine. J Clin Invest 2009; 119:16.</a></li><li><a class="nounderline abstract_t">Arbab MA, Wiklund L, Svendgaard NA. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. Neuroscience 1986; 19:695.</a></li><li><a class="nounderline abstract_t">Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 2002; 125:1496.</a></li><li><a class="nounderline abstract_t">Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 2003; 126:1801.</a></li><li class="breakAll">Kruge L, Young RF. Specialized features of the trigeminal nerve and its central connections. In: The Cranial Nerves, Samii M, Janetta PJ (Eds), Springer-Verlag, Berlin 1981. p.273.</li><li><a class="nounderline abstract_t">Sessle BJ, Hu JW, Dubner R, Lucier GE. Functional properties of neurons in cat trigeminal subnucleus caudalis (medullary dorsal horn). II. Modulation of responses to noxious and nonnoxious stimuli by periaqueductal gray, nucleus raphe magnus, cerebral cortex, and afferent influences, and effect of naloxone. J Neurophysiol 1981; 45:193.</a></li><li><a class="nounderline abstract_t">Wise SP, Jones EG. Cells of origin and terminal distribution of descending projections of the rat somatic sensory cortex. J Comp Neurol 1977; 175:129.</a></li><li><a class="nounderline abstract_t">Zagami AS, Lambert GA. Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat. Neurosci Lett 1991; 121:187.</a></li><li><a class="nounderline abstract_t">Jacquin MF, Chiaia NL, Haring JH, Rhoades RW. Intersubnuclear connections within the rat trigeminal brainstem complex. Somatosens Mot Res 1990; 7:399.</a></li><li><a class="nounderline abstract_t">Renehan WE, Jacquin MF, Mooney RD, Rhoades RW. Structure-function relationships in rat medullary and cervical dorsal horns. II. Medullary dorsal horn cells. J Neurophysiol 1986; 55:1187.</a></li><li><a class="nounderline abstract_t">Huerta MF, Frankfurter A, Harting JK. Studies of the principal sensory and spinal trigeminal nuclei of the rat: projections to the superior colliculus, inferior olive, and cerebellum. J Comp Neurol 1983; 220:147.</a></li><li><a class="nounderline abstract_t">Mantle-St John LA, Tracey DJ. Somatosensory nuclei in the brainstem of the rat: independent projections to the thalamus and cerebellum. J Comp Neurol 1987; 255:259.</a></li><li><a class="nounderline abstract_t">Bernard JF, Peschanski M, Besson JM. A possible spino (trigemino)-ponto-amygdaloid pathway for pain. Neurosci Lett 1989; 100:83.</a></li><li><a class="nounderline abstract_t">Hayashi H, Tabata T. Pulpal and cutaneous inputs to somatosensory neurons in the parabrachial area of the cat. Brain Res 1990; 511:177.</a></li><li><a class="nounderline abstract_t">Huang LY. Origin of thalamically projecting somatosensory relay neurons in the immature rat. Brain Res 1989; 495:108.</a></li><li><a class="nounderline abstract_t">Kemplay S, Webster KE. A quantitative study of the projections of the gracile, cuneate and trigeminal nuclei and of the medullary reticular formation to the thalamus in the rat. Neuroscience 1989; 32:153.</a></li><li><a class="nounderline abstract_t">Peschanski M, Roudier F, Ralston HJ 3rd, Besson JM. Ultrastructural analysis of the terminals of various somatosensory pathways in the ventrobasal complex of the rat thalamus: an electron-microscopic study using wheatgerm agglutinin conjugated to horseradish peroxidase as an axonal tracer. Somatosens Res 1985; 3:75.</a></li><li><a class="nounderline abstract_t">Shigenaga Y, Nakatani Z, Nishimori T, et al. The cells of origin of cat trigeminothalamic projections: especially in the caudal medulla. Brain Res 1983; 277:201.</a></li><li><a class="nounderline abstract_t">Craig AD Jr, Burton H. Spinal and medullary lamina I projection to nucleus submedius in medial thalamus: a possible pain center. J Neurophysiol 1981; 45:443.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23:193.</a></li><li><a class="nounderline abstract_t">Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001; 57:132.</a></li><li><a class="nounderline abstract_t">Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001; 89:107.</a></li><li><a class="nounderline abstract_t">Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384:560.</a></li><li><a class="nounderline abstract_t">Kaube H, Katsarava Z, Przywara S, et al. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002; 58:1234.</a></li><li><a class="nounderline abstract_t">Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658.</a></li><li><a class="nounderline abstract_t">Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001; 357:1016.</a></li><li><a class="nounderline abstract_t">Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44:747.</a></li><li><a class="nounderline abstract_t">Granziera C, DaSilva AF, Snyder J, et al. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med 2006; 3:e402.</a></li><li><a class="nounderline abstract_t">Rocca MA, Ceccarelli A, Falini A, et al. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke 2006; 37:1765.</a></li><li><a class="nounderline abstract_t">Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001; 41:629.</a></li><li><a class="nounderline abstract_t">Deen M, Christensen CE, Hougaard A, et al. Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia 2017; 37:251.</a></li><li><a class="nounderline abstract_t">Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27:1293.</a></li><li><a class="nounderline abstract_t">Panconesi A. Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 2008; 9:267.</a></li><li><a class="nounderline abstract_t">Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394:1765.</a></li><li><a class="nounderline abstract_t">Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 2011; 77:281.</a></li><li><a class="nounderline abstract_t">Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48.</a></li><li><a class="nounderline abstract_t">Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.</a></li><li><a class="nounderline abstract_t">Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999; 52:1622.</a></li><li><a class="nounderline abstract_t">Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998; 8:327.</a></li><li><a class="nounderline abstract_t">Post MC, Letteboer TG, Mager JJ, et al. A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005; 128:2485.</a></li><li><a class="nounderline abstract_t">Rundek T, Elkind MS, Di Tullio MR, et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation 2008; 118:1419.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia 2008; 28:531.</a></li><li><a class="nounderline abstract_t">Kurth T, Tzourio C, Bousser MG. Migraine: a matter of the heart? Circulation 2008; 118:1405.</a></li><li><a class="nounderline abstract_t">Pierangeli G, Cevoli S, Zanigni S, et al. The role of cardiac diseases in the comorbidity between migraine and stroke. Neurol Sci 2004; 25 Suppl 3:S129.</a></li><li><a class="nounderline abstract_t">Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003; 107:5.</a></li><li><a class="nounderline abstract_t">Lance JW, Anthony M. Some clinical aspects of migraine. A prospective survey of 500 patients. Arch Neurol 1966; 15:356.</a></li><li><a class="nounderline abstract_t">Merikangas KR, Risch NJ, Merikangas JR, et al. Migraine and depression: association and familial transmission. J Psychiatr Res 1988; 22:119.</a></li><li><a class="nounderline abstract_t">Devoto M, Lozito A, Staffa G, et al. Segregation analysis of migraine in 128 families. Cephalalgia 1986; 6:101.</a></li><li><a class="nounderline abstract_t">Honkasalo ML, Kaprio J, Winter T, et al. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache 1995; 35:70.</a></li><li><a class="nounderline abstract_t">Lafrenière RG, Cader MZ, Poulin JF, et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med 2010; 16:1157.</a></li><li><a class="nounderline abstract_t">Brennan KC, Bates EA, Shapiro RE, et al. Casein kinase iδ mutations in familial migraine and advanced sleep phase. Sci Transl Med 2013; 5:183ra56, 1.</a></li><li><a class="nounderline abstract_t">de Vries B, Anttila V, Freilinger T, et al. Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia 2016; 36:604.</a></li><li><a class="nounderline abstract_t">Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646.</a></li><li><a class="nounderline abstract_t">Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet 2021; 397:1485.</a></li><li><a class="nounderline abstract_t">Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994; 44:S17.</a></li><li><a class="nounderline abstract_t">Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68:343.</a></li><li><a class="nounderline abstract_t">GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17:954.</a></li><li><a class="nounderline abstract_t">Peng KP, Chen YT, Fuh JL, et al. Increased risk of Bell palsy in patients with migraine: a nationwide cohort study. Neurology 2015; 84:116.</a></li><li><a class="nounderline abstract_t">Chu CH, Liu CJ, Fuh JL, et al. Migraine is a risk factor for sudden sensorineural hearing loss: a nationwide population-based study. Cephalalgia 2013; 33:80.</a></li><li><a class="nounderline abstract_t">Yang CP, Chen YT, Fuh JL, Wang SJ. Migraine and Risk of Ocular Motor Cranial Nerve Palsies: A Nationwide Cohort Study. Ophthalmology 2016; 123:191.</a></li><li><a class="nounderline abstract_t">Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am 2001; 85:911.</a></li><li><a class="nounderline abstract_t">Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27:394.</a></li><li><a class="nounderline abstract_t">Onderwater GLJ, van Oosterhout WPJ, Schoonman GG, et al. Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine. Eur J Neurol 2019; 26:588.</a></li><li><a class="nounderline abstract_t">Davis-Martin RE, Polk AN, Smitherman TA. Alcohol Use as a Comorbidity and Precipitant of Primary Headache: Review and Meta-analysis. Curr Pain Headache Rep 2017; 21:42.</a></li><li><a class="nounderline abstract_t">Panconesi A. Alcohol and migraine: trigger factor, consumption, mechanisms. A review. J Headache Pain 2008; 9:19.</a></li><li><a class="nounderline abstract_t">Devi A, Levin M, Waterhouse AL. Inhibition of ALDH2 by quercetin glucuronide suggests a new hypothesis to explain red wine headaches. Sci Rep 2023; 13:19503.</a></li><li><a class="nounderline abstract_t">Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache 2005; 45:904.</a></li><li><a class="nounderline abstract_t">Rains JC, Poceta JS. Headache and sleep disorders: review and clinical implications for headache management. Headache 2006; 46:1344.</a></li><li><a class="nounderline abstract_t">Cevoli S, Giannini G, Favoni V, et al. Migraine and sleep disorders. Neurol Sci 2012; 33 Suppl 1:S43.</a></li><li><a class="nounderline abstract_t">Freedom T, Evans RW. Headache and sleep. Headache 2013; 53:1358.</a></li><li><a class="nounderline abstract_t">Walters AB, Hamer JD, Smitherman TA. Sleep disturbance and affective comorbidity among episodic migraineurs. Headache 2014; 54:116.</a></li><li><a class="nounderline abstract_t">Yoo A, Vgontzas A, Chung J, et al. The association between multidimensional sleep health and migraine burden among patients with episodic migraine. J Clin Sleep Med 2023; 19:309.</a></li><li><a class="nounderline abstract_t">Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology 2006; 66:545.</a></li><li><a class="nounderline abstract_t">Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006; 67:252.</a></li><li><a class="nounderline abstract_t">Bigal ME, Tsang A, Loder E, et al. Body mass index and episodic headaches: a population-based study. Arch Intern Med 2007; 167:1964.</a></li><li><a class="nounderline abstract_t">Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013; 53:413.</a></li><li><a class="nounderline abstract_t">Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004; 44:865.</a></li><li><a class="nounderline abstract_t">Laurell K, Artto V, Bendtsen L, et al. Premonitory symptoms in migraine: A cross-sectional study in 2714 persons. Cephalalgia 2016; 36:951.</a></li><li><a class="nounderline abstract_t">Hansen JM, Lipton RB, Dodick DW, et al. Migraine headache is present in the aura phase: a prospective study. Neurology 2012; 79:2044.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996; 119 ( Pt 2):355.</a></li><li><a class="nounderline abstract_t">Cutrer FM, Huerter K. Migraine aura. Neurologist 2007; 13:118.</a></li><li><a class="nounderline abstract_t">Fisher CM. Late-life migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neurol Sci 1980; 7:9.</a></li><li><a class="nounderline abstract_t">Vongvaivanich K, Lertakyamanee P, Silberstein SD, Dodick DW. Late-life migraine accompaniments: A narrative review. Cephalalgia 2015; 35:894.</a></li><li><a class="nounderline abstract_t">Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35:387.</a></li><li><a class="nounderline abstract_t">Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia 2006; 26:548.</a></li><li><a class="nounderline abstract_t">Wang YF, Fuh JL, Chen SP, et al. Clinical correlates and diagnostic utility of osmophobia in migraine. Cephalalgia 2012; 32:1180.</a></li><li><a class="nounderline abstract_t">Giffin NJ, Lipton RB, Silberstein SD, et al. The migraine postdrome: An electronic diary study. Neurology 2016; 87:309.</a></li><li><a class="nounderline abstract_t">Kelman L. The postdrome of the acute migraine attack. Cephalalgia 2006; 26:214.</a></li><li><a class="nounderline abstract_t">Quintela E, Castillo J, Muñoz P, Pascual J. Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia 2006; 26:1051.</a></li><li><a class="nounderline abstract_t">Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614.</a></li><li><a class="nounderline abstract_t">Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008; 70:1525.</a></li><li><a class="nounderline abstract_t">Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 2004; 63:848.</a></li><li><a class="nounderline abstract_t">Corbett JJ. Neuro-ophthalmic complications of migraine and cluster headaches. Neurol Clin 1983; 1:973.</a></li><li><a class="nounderline abstract_t">Grosberg BM, Solomon S, Friedman DI, Lipton RB. Retinal migraine reappraised. Cephalalgia 2006; 26:1275.</a></li><li><a class="nounderline abstract_t">VanderPluym JH, Mangipudi K, Mbonde AA, et al. Incidence of Status Migrainosus in Olmsted County, Minnesota, United States: Characterization and Predictors of Recurrence. Neurology 2023; 100:e255.</a></li><li><a class="nounderline abstract_t">Smetana GW. The diagnostic value of historical features in primary headache syndromes: a comprehensive review. Arch Intern Med 2000; 160:2729.</a></li><li><a class="nounderline abstract_t">Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.</a></li><li><a class="nounderline abstract_t">Kumar KL, Cooney TG. Headaches. Med Clin North Am 1995; 79:261.</a></li><li><a class="nounderline abstract_t">Evans RW. Diagnostic testing for migraine and other primary headaches. Neurol Clin 2009; 27:393.</a></li><li><a class="nounderline abstract_t">Kent DL, Haynor DR, Longstreth WT Jr, Larson EB. The clinical efficacy of magnetic resonance imaging in neuroimaging. Ann Intern Med 1994; 120:856.</a></li></ol></div><div id="topicVersionRevision">Topic 3348 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628527" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathophysiology of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33211930" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479724" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Advances in the basic and clinical science of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23578774" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vasodilation out of the picture as a cause of migraine headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23578775" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105379" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug therapy of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Spreading depression of activity in the cerebral cortex</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pial circulation and spreading depression of activity in cerebral cortex</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287655" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mechanisms of migraine aura revealed by functional MRI in human visual cortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382735" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449592" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Spreading depression triggers headache by activating neuronal Panx1 channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146242" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cortical spreading depression activates and upregulates MMP-9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821897" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104145" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Deciphering migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491965" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077000" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821523" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821523" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6257861" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Functional properties of neurons in cat trigeminal subnucleus caudalis (medullary dorsal horn). II. Modulation of responses to noxious and nonnoxious stimuli by periaqueductal gray, nucleus raphe magnus, cerebral cortex, and afferent influences, and effect of naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/408380" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cells of origin and terminal distribution of descending projections of the rat somatic sensory cortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1708477" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2291376" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intersubnuclear connections within the rat trigeminal brainstem complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3734854" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Structure-function relationships in rat medullary and cervical dorsal horns. II. Medullary dorsal horn cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6643723" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Studies of the principal sensory and spinal trigeminal nuclei of the rat: projections to the superior colliculus, inferior olive, and cerebellum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819016" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Somatosensory nuclei in the brainstem of the rat: independent projections to the thalamus and cerebellum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2474780" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A possible spino (trigemino)-ponto-amygdaloid pathway for pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2331615" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulpal and cutaneous inputs to somatosensory neurons in the parabrachial area of the cat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2776029" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Origin of thalamically projecting somatosensory relay neurons in the immature rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2586747" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A quantitative study of the projections of the gracile, cuneate and trigeminal nuclei and of the medullary reticular formation to the thalamus in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4070893" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ultrastructural analysis of the terminals of various somatosensory pathways in the ventrobasal complex of the rat thalamus: an electron-microscopic study using wheatgerm agglutinin conjugated to horseradish peroxidase as an axonal tracer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6640296" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The cells of origin of cat trigeminothalamic projections: especially in the caudal medulla.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6783739" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Spinal and medullary lamina I projection to nucleus submedius in medial thalamus: a possible pain center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2454066" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445643" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11166465" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Deconstructing migraine headache into peripheral and central sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8955268" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sensitization of meningeal sensory neurons and the origin of headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971092" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7585147" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Brain stem activation in spontaneous human migraine attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11293599" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Brainstem activation specific to migraine headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15330820" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Posterior hypothalamic and brainstem activation in hemicrania continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17048979" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Anatomical alterations of the visual motion processing network in migraine with and without aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728687" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11554950" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27013238" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serotonergic mechanisms in the migraine brain - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17970989" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serotonin and migraine: biology and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668197" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Serotonin and migraine: a reconsideration of the central theory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31668411" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Targeting calcitonin gene-related peptide: a new era in migraine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768598" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CGRP: sensory neuropeptide with multiple neurologic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11993614" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : CGRP may play a causative role in migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1699472" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8388188" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11872892" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10331688" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774749" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236913" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794393" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355348" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Patent foramen ovale and migraine: a quantitative systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824652" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Migraine: a matter of the heart?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15549521" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The role of cardiac diseases in the comorbidity between migraine and stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12515733" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Contemporary management of patent foramen ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5912494" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Some clinical aspects of migraine. A prospective survey of 500 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3404480" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Migraine and depression: association and familial transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3527442" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Segregation analysis of migraine in 128 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737864" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Migraine and concomitant symptoms among 8167 adult twin pairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20871611" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636092" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Casein kinase iδmutations in familial migraine and advanced sleep phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25633374" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11554952" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevalence and burden of migraine in the United States: data from the American Migraine Study II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33773613" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Migraine: epidemiology and systems of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008222" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Migraine prevalence. A review of population-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261680" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Migraine prevalence, disease burden, and the need for preventive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30353868" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25520313" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Increased risk of Bell palsy in patients with migraine: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23197354" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Migraine is a risk factor for sudden sensorineural hearing loss: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26460000" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Migraine and Risk of Ocular Motor Cranial Nerve Palsies: A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11480265" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Toward a rational understanding of migraine trigger factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403039" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The triggers or precipitants of the acute migraine attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30565341" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844083" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Alcohol Use as a Comorbidity and Precipitant of Primary Headache: Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231712" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Alcohol and migraine: trigger factor, consumption, mechanisms. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37985790" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Inhibition of ALDH2 by quercetin glucuronide suggests a new hypothesis to explain red wine headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985108" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040332" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Headache and sleep disorders: review and clinical implications for headache management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22644169" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Migraine and sleep disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23848227" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Headache and sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23808359" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sleep disturbance and affective comorbidity among episodic migraineurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36263856" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The association between multidimensional sleep health and migraine burden among patients with episodic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354886" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Obesity and migraine: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864817" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Obesity is a risk factor for transformed migraine but not chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923596" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Body mass index and episodic headaches: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23278169" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The evolution of a migraine attack - a review of recent evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15447695" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643378" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Premonitory symptoms in migraine: A cross-sectional study in 2714 persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115208" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Migraine headache is present in the aura phase: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800932" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A nosographic analysis of the migraine aura in a general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17495755" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Migraine aura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7388704" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Late-life migraine accompaniments as a cause of unexplained transient ischemic attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25505036" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Late-life migraine accompaniments: A narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7672955" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Migraine symptoms: results of a survey of self-reported migraineurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16674763" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The relationship between migraine pain and other associated symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23038716" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical correlates and diagnostic utility of osmophobia in migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27335112" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The migraine postdrome: An electronic diary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426278" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The postdrome of the acute migraine attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16919055" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10805332" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : An association between migraine and cutaneous allodynia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18427069" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Prevalence and characteristics of allodynia in headache sufferers: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365135" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical recognition of allodynia in migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6390159" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Neuro-ophthalmic complications of migraine and cluster headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059434" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Retinal migraine reappraised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36175145" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Incidence of Status Migrainosus in Olmsted County, Minnesota, United States: Characterization and Predictors of Recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025782" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The diagnostic value of historical features in primary headache syndromes: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10993991" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877390" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289222" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Diagnostic testing for migraine and other primary headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818632" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The clinical efficacy of magnetic resonance imaging in neuroimaging.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
